Eli Lilly Stock Dips on Q4 2024 Revenue Guidance Miss
Eli Lilly’s Q4 2024 revenue guidance missed Wall Street expectations, causing a 6% stock dip. Slower U.S. incretin market growth and lower channel inventory contributed to the $13.5B projection, despite a 45% year-over-year increase.
Eli Lilly Stock Dips on Q4 2024 Revenue Guidance Miss Read More »